Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases

A phase I clinical trial (a type of research study) for people with human epidermal growth factor receptor 2 (HER-2) positive breast cancer with metastasis to the brain. This research study will evaluate how well brain metastases can be controlled using a type of radiation therapy known as stereotactic radiosurgery (SRS) when combined with the therapeutic agent Trastuzumab Deruxtecan (T-DXd). The combined use of SRS with T-DXd is considered investigational.

NCT Number	NCT07454668
Lead Sponsor	Baptist Health South Florida Collaborators: National Brain Tumor Society
Conditions	Breast Cancer, HER2-positive Breast Cancer, Brain Metastases, Cancer, Cancer Metastatic
Enrollment	20 participants
Start Date	2026-06
Primary Completion	2028-07 (estimated)
Study Completion	2029-07 (estimated)
Updated on ClinicalTrials.gov	2026-03-06